We report a 45-year-old female with AML who underwent a T cell-depleted sibling allograft and relapsed a year later with extramedullary disease involving the lung parenchyma and presenting with the clinical and radiological features of interstitial pneumonitis. The patient was treated with donor lymphocyte infusion (DLI) resulting in complete resolution of the radiological signs. The unusual presentation and the management options are discussed. Keywords: granulocytic sarcoma; allogeneic bone marrow transplantation; interstitial pneumonitis; donor lymphocyte infusion; adoptive immunotherapy Extramedullary recurrence of acute myeloid leukaemia after chemotherapy or following bone marrow transplantation is unusual. We describe a unique case of diffuse intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis in a 45-year-old female who had undergone an allogeneic bone marrow transplant 12 months previously.
Extramedullary recurrence of acute myeloid leukaemia after chemotherapy or following bone marrow transplantation is unusual. We describe a unique case of diffuse intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis in a 45-year-old female who had undergone an allogeneic bone marrow transplant 12 months previously.
Case report
A 45-year-old Indian female presented to her GP with a 2-week history of tiredness. The full blood count revealed anaemia and she was referred to the local hospital for further investigations. A bone marrow aspirate and trephine biopsy showed trilineage myelodysplasia with Ͻ2% blasts. Cytogenetics were normal. Three months later a regular follow-up showed blasts on the peripheral blood film and a diagnosis of AML was made on the bone marrow aspirate. Cytogenetics remained normal. She was treated according to the MRC AMLXII protocol with two courses of ADE (daunorubicin, etoposide, cytarabine), one course of MACE (amasacrine, cytarabine, etoposide) and one course of MIDAC (mitozantrone, cytarabine), achieving CR after the first course. Subsequently, she underwent a T cell-depleted bone marrow transplant from her HLA-identical sister. Conditioning consisted of CAMPATH 1G 20 mg/day for 5 days (day −9 to −5); thiotepa 5 mg/kg/day for 2 days (day −8 to −7) cyclophosphamide 60 mg/kg/day for 2 days (day −6 to −5) and total body irradiation, 1440 cGy in eight fractions (day −4 to −1). T cell depletion was performed ex vivo using Campath 1M. The patient had an uneventful post-transplant course. She engrafted on day +16 (neutrophils Ͼ0.5 × 10 9 /l). Recovery of platelets was achieved on day +22 (Ͼ50 × 10 9 /l). She did not experience any signs of acute GVHD and was discharged on day +23. On day +45 she tested CMV PCR positive in the blood for the second consecutive week and in accordance with the surveillance/treatment protocol was treated with 14 days of ganciclovir (5 mg/kg twice daily), rendering her CMV PCR negative. Follow-up was uncomplicated until day +365 when she was again admitted to the hospital with a 2-week history of non-productive cough and pyrexia. Extensive investigations failed to demonstrate any infectious cause for the pyrexia but a high resolution CT scan of the chest revealed generalised ground glass shadowing, with focal areas of reduced vascularity giving a mosaic perfusion pattern. Appearances suggested areas of bronchiolitis obliterans due to old infection with the possibility of more active infection giving the parenchyma appearances. Small and borderline enlarged lymph nodes were also present in the mediastinum.
Bronchoalveolar lavage (BAL) was performed but no isolates were found on subsequent cultures. Repeated CMV PCR blood tests were negative and the patient was treated with conventional antimicrobials resulting in partial resolution of the symptoms and the pyrexia. A repeat high resolution CT scan of the chest revealed progression with focal parenchymal shadows, thickening of the interlobular septae and small airways disease with bronchial wall thickening and several small nodules posteriorly in the upper and lower lobes (Figure 1 ). The mediastinal appearances were (Figure 2 ). Staining for cytokeratin was negative (MNF116). There was no evidence of leukaemia in the marrow. Staging CT showed no other deposits. The patient received a donor lymphocyte infusion (DLI) with a T cell content of 1 × 10 7 /kg and 5 weeks later developed grade II skin GVHD which settled on topical and oral steroids. Further follow-up 6 months after the DLI infusion showed resolution of the focal infiltrates, nodules and interlobular thickening (Figure 3) . The bone marrow remained clear. At 12 months post-DLI the patient remains well and asymptomatic.
Discussion
Granulocytic sarcoma may be diagnosed in a number of different haematological malignancies, AML being the most frequent followed by chronic myeloid leukaemia and myelodysplastic syndromes. Granulocytic sarcoma is considered to represent the first manifestation of systemic disease and can precede, accompany or complicate the diagnosis of AML. According to most series and reports the majority of patients with granulocytic sarcoma without evidence of marrow involvement at diagnosis, inevitably progress to overt AML within a matter of months and therefore are treated as if they have AML. The clinical characteristics at diagnosis vary according to the site of development of the soft tissue tumour. Nearly half of the granulocytic sarcoma sites involve either the subcutaneous tissues or the orbits especially in the paediatric population. Other sites of involvement which have been reported in the literature include bone, periosteum and adjacent tissues, vertebral paravertebral extra-and epidural space, brain, iris, salivary glands, thyroid, ovaries, testies, breast, lymph nodes, mediastinum, small and large bowel uterus, bladder, paranasal sinuses and gingiva.
Granulocytic sarcoma after allogeneic BMT is a relatively rare event. In a retrospective European multicenter survey 1 of 3071 patients who underwent an allogeneic bone marrow transplant the occurrence of GS as isolated extramedullary relapse after the transplant was 0.65%. A higher frequency of 3.6% has been reported in another single institution study. 2 The management of GS is controversial and the optimum treatment has yet to be established. The EBMT study included several treatment modalities: chemotherapy or radiotherapy alone, chemotherapy combined with radiotherapy, excision surgery, donor lymphocyte infusion (DLI) and a second transplant. Even though some patients can become long-term survivors, especially those who are transplanted early (46% 2-year survival in CR1 vs 0% in ϾCR1), the optimal approach remains unclear. Our patient showed complete resolution of the abnormal radiological findings following the DLI. Interstitial pneumonitis following allogeneic BMT is a common and often fatal complication. The causes of this syndrome include chemor-adiotherapy, viral infections, Pneumocystis carinii, fungal infections, and more rarely, pneumonia with legionella, mycoplasma, toxoplasma, chronic GVHD and pulmonary haemorrhage. Our review of the literature suggests that this is the first reported case of granulocytic sarcoma presenting with such an unusual picture of interstitial pneumonitis.
Intrathoracic granulocytic sarcoma frequently involves the mediastinum. The disease has been demonstrated on CT as diffuse infiltration of fat or small nodules within the mediastinal fat rather than lymphadenopathy. 3 Our case was different in that there was no infiltration, but discrete borderline lymphadenopathy was present which was unchanged following treatment. Other features such as pleural effusion masses or a pericardial effusion were not seen in our patient. Lung involvement has been documented but is rare and manifests usually as nodules. Our case is unusual in that intrapulmonary nodules were not a major feature, but there was thickening of the interlobular septae and small airways disease.
In summary, we describe a histologically proven case of granulocytic sarcoma following bone marrow transplant for AML and presenting with an unusual pattern of interstitial pneumonitis. The response of this patient's granulocytic sarcoma to DLI is also unusual, as it has been shown that it is often extramedullary disease that 'escapes' from the antileukaemic effects of DLI in patients with AML.
